Chemotherapy of head and neck cancer: Combination treatment with cyclophosphamide, adriamycin, methotrexate, and bleomycin
A combination of cyclophosphamide, adriamycin, methotrexate, and bleomycin (CAMB) was explored in patients with advanced, nonresectable epidermoid carcinoma from primary sites in the head and neck, recurrent or persistent after radiation or surgery. Objective regression (greater than 50%) of measura...
Gespeichert in:
| Veröffentlicht in: | Medical and pediatric oncology 1977, Vol.3 (3), p.301-309 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 309 |
|---|---|
| container_issue | 3 |
| container_start_page | 301 |
| container_title | Medical and pediatric oncology |
| container_volume | 3 |
| creator | Wittes, Robert E. Spiro, Ronald H. Shah, Jatin Gerold, Frank P. Koven, Bernard Strong, Elliot W. |
| description | A combination of cyclophosphamide, adriamycin, methotrexate, and bleomycin (CAMB) was explored in patients with advanced, nonresectable epidermoid carcinoma from primary sites in the head and neck, recurrent or persistent after radiation or surgery. Objective regression (greater than 50%) of measurable tumor was present in 35% of the patients. The median duration of response was 2.5 months. Median survival of responders was slightly less than the nonresponders, but the difference was not significant. Drug‐related morbidity was substantial; leukopenia, mucositis, and weight loss were the most frequent major side effects. Three deaths were attributable to the regimen. The results seem comparable to those one might expect from methotrexate alone. |
| doi_str_mv | 10.1002/mpo.2950030312 |
| format | Article |
| fullrecord | <record><control><sourceid>istex_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_mpo_2950030312</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_WNG_S6RDJLGN_Z</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3762-359d27ff23115429f9558232fde279b9e507d319842851a0029f322aa65d233c3</originalsourceid><addsrcrecordid>eNqFkM1O4zAURi0EgsKwZcPGD0CKf-okZocKFEYdGM2AQGws175RDHUcOUYQnp5AEaNZsbKs756zOAjtUTKmhLBD34Yxk4IQTjhla2hEicwzSendOhoRIsuMCs620HbXPZDhL4tyE22Ugk3kCL1Oa_Ah1RB12-NQ4Rq0xbqxuAHziI1uDMQjPA1-4RqdXGhwiqCThybhZ5dqbHqzDG0durbW3lk4wNpGp31vXHOAPaQ6DMSLTu_L4F0sIXyMP9BGpZcd7H6-O-jm7PR6ep7Nr2YX0-N5ZniRs4wLaVlRVYxTKiZMVlKIknFWWWCFXEgQpLCcynLCSkH1UERWnDGtc2EZ54bvoPHKa2LougiVaqPzOvaKEvVeUA0F1b-CA7C_AtqnhQf7df6RbFjlan12S-i_calfv6_-M2cr1nUJXr5YHR9VXvBCqNvLmfqb_zn5OZ9dqnv-BjVFjQg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Chemotherapy of head and neck cancer: Combination treatment with cyclophosphamide, adriamycin, methotrexate, and bleomycin</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Wittes, Robert E. ; Spiro, Ronald H. ; Shah, Jatin ; Gerold, Frank P. ; Koven, Bernard ; Strong, Elliot W.</creator><creatorcontrib>Wittes, Robert E. ; Spiro, Ronald H. ; Shah, Jatin ; Gerold, Frank P. ; Koven, Bernard ; Strong, Elliot W.</creatorcontrib><description>A combination of cyclophosphamide, adriamycin, methotrexate, and bleomycin (CAMB) was explored in patients with advanced, nonresectable epidermoid carcinoma from primary sites in the head and neck, recurrent or persistent after radiation or surgery. Objective regression (greater than 50%) of measurable tumor was present in 35% of the patients. The median duration of response was 2.5 months. Median survival of responders was slightly less than the nonresponders, but the difference was not significant. Drug‐related morbidity was substantial; leukopenia, mucositis, and weight loss were the most frequent major side effects. Three deaths were attributable to the regimen. The results seem comparable to those one might expect from methotrexate alone.</description><identifier>ISSN: 0098-1532</identifier><identifier>EISSN: 1096-911X</identifier><identifier>DOI: 10.1002/mpo.2950030312</identifier><identifier>PMID: 85249</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Bleomycin - administration & dosage ; Bleomycin - adverse effects ; Bleomycin - therapeutic use ; Carcinoma, Squamous Cell - drug therapy ; Carcinoma, Squamous Cell - mortality ; chemotherapy ; Cyclophosphamide - administration & dosage ; Cyclophosphamide - adverse effects ; Cyclophosphamide - therapeutic use ; Doxorubicin - administration & dosage ; Doxorubicin - adverse effects ; Doxorubicin - therapeutic use ; Drug Evaluation ; Drug Therapy, Combination ; epidermoid carcinoma ; Female ; head and neck cancer ; Head and Neck Neoplasms - drug therapy ; Head and Neck Neoplasms - mortality ; Humans ; Male ; Methotrexate - administration & dosage ; Methotrexate - adverse effects ; Methotrexate - therapeutic use</subject><ispartof>Medical and pediatric oncology, 1977, Vol.3 (3), p.301-309</ispartof><rights>Copyright © 1977 Wiley‐Liss, Inc., A Wiley Company</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3762-359d27ff23115429f9558232fde279b9e507d319842851a0029f322aa65d233c3</citedby><cites>FETCH-LOGICAL-c3762-359d27ff23115429f9558232fde279b9e507d319842851a0029f322aa65d233c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fmpo.2950030312$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fmpo.2950030312$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,4024,27923,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/85249$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wittes, Robert E.</creatorcontrib><creatorcontrib>Spiro, Ronald H.</creatorcontrib><creatorcontrib>Shah, Jatin</creatorcontrib><creatorcontrib>Gerold, Frank P.</creatorcontrib><creatorcontrib>Koven, Bernard</creatorcontrib><creatorcontrib>Strong, Elliot W.</creatorcontrib><title>Chemotherapy of head and neck cancer: Combination treatment with cyclophosphamide, adriamycin, methotrexate, and bleomycin</title><title>Medical and pediatric oncology</title><addtitle>Med. Pediatr. Oncol</addtitle><description>A combination of cyclophosphamide, adriamycin, methotrexate, and bleomycin (CAMB) was explored in patients with advanced, nonresectable epidermoid carcinoma from primary sites in the head and neck, recurrent or persistent after radiation or surgery. Objective regression (greater than 50%) of measurable tumor was present in 35% of the patients. The median duration of response was 2.5 months. Median survival of responders was slightly less than the nonresponders, but the difference was not significant. Drug‐related morbidity was substantial; leukopenia, mucositis, and weight loss were the most frequent major side effects. Three deaths were attributable to the regimen. The results seem comparable to those one might expect from methotrexate alone.</description><subject>Adult</subject><subject>Bleomycin - administration & dosage</subject><subject>Bleomycin - adverse effects</subject><subject>Bleomycin - therapeutic use</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Carcinoma, Squamous Cell - mortality</subject><subject>chemotherapy</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Cyclophosphamide - adverse effects</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Doxorubicin - administration & dosage</subject><subject>Doxorubicin - adverse effects</subject><subject>Doxorubicin - therapeutic use</subject><subject>Drug Evaluation</subject><subject>Drug Therapy, Combination</subject><subject>epidermoid carcinoma</subject><subject>Female</subject><subject>head and neck cancer</subject><subject>Head and Neck Neoplasms - drug therapy</subject><subject>Head and Neck Neoplasms - mortality</subject><subject>Humans</subject><subject>Male</subject><subject>Methotrexate - administration & dosage</subject><subject>Methotrexate - adverse effects</subject><subject>Methotrexate - therapeutic use</subject><issn>0098-1532</issn><issn>1096-911X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1977</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkM1O4zAURi0EgsKwZcPGD0CKf-okZocKFEYdGM2AQGws175RDHUcOUYQnp5AEaNZsbKs756zOAjtUTKmhLBD34Yxk4IQTjhla2hEicwzSendOhoRIsuMCs620HbXPZDhL4tyE22Ugk3kCL1Oa_Ah1RB12-NQ4Rq0xbqxuAHziI1uDMQjPA1-4RqdXGhwiqCThybhZ5dqbHqzDG0durbW3lk4wNpGp31vXHOAPaQ6DMSLTu_L4F0sIXyMP9BGpZcd7H6-O-jm7PR6ep7Nr2YX0-N5ZniRs4wLaVlRVYxTKiZMVlKIknFWWWCFXEgQpLCcynLCSkH1UERWnDGtc2EZ54bvoPHKa2LougiVaqPzOvaKEvVeUA0F1b-CA7C_AtqnhQf7df6RbFjlan12S-i_calfv6_-M2cr1nUJXr5YHR9VXvBCqNvLmfqb_zn5OZ9dqnv-BjVFjQg</recordid><startdate>1977</startdate><enddate>1977</enddate><creator>Wittes, Robert E.</creator><creator>Spiro, Ronald H.</creator><creator>Shah, Jatin</creator><creator>Gerold, Frank P.</creator><creator>Koven, Bernard</creator><creator>Strong, Elliot W.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>1977</creationdate><title>Chemotherapy of head and neck cancer: Combination treatment with cyclophosphamide, adriamycin, methotrexate, and bleomycin</title><author>Wittes, Robert E. ; Spiro, Ronald H. ; Shah, Jatin ; Gerold, Frank P. ; Koven, Bernard ; Strong, Elliot W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3762-359d27ff23115429f9558232fde279b9e507d319842851a0029f322aa65d233c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1977</creationdate><topic>Adult</topic><topic>Bleomycin - administration & dosage</topic><topic>Bleomycin - adverse effects</topic><topic>Bleomycin - therapeutic use</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Carcinoma, Squamous Cell - mortality</topic><topic>chemotherapy</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Cyclophosphamide - adverse effects</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Doxorubicin - administration & dosage</topic><topic>Doxorubicin - adverse effects</topic><topic>Doxorubicin - therapeutic use</topic><topic>Drug Evaluation</topic><topic>Drug Therapy, Combination</topic><topic>epidermoid carcinoma</topic><topic>Female</topic><topic>head and neck cancer</topic><topic>Head and Neck Neoplasms - drug therapy</topic><topic>Head and Neck Neoplasms - mortality</topic><topic>Humans</topic><topic>Male</topic><topic>Methotrexate - administration & dosage</topic><topic>Methotrexate - adverse effects</topic><topic>Methotrexate - therapeutic use</topic><toplevel>online_resources</toplevel><creatorcontrib>Wittes, Robert E.</creatorcontrib><creatorcontrib>Spiro, Ronald H.</creatorcontrib><creatorcontrib>Shah, Jatin</creatorcontrib><creatorcontrib>Gerold, Frank P.</creatorcontrib><creatorcontrib>Koven, Bernard</creatorcontrib><creatorcontrib>Strong, Elliot W.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Medical and pediatric oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wittes, Robert E.</au><au>Spiro, Ronald H.</au><au>Shah, Jatin</au><au>Gerold, Frank P.</au><au>Koven, Bernard</au><au>Strong, Elliot W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chemotherapy of head and neck cancer: Combination treatment with cyclophosphamide, adriamycin, methotrexate, and bleomycin</atitle><jtitle>Medical and pediatric oncology</jtitle><addtitle>Med. Pediatr. Oncol</addtitle><date>1977</date><risdate>1977</risdate><volume>3</volume><issue>3</issue><spage>301</spage><epage>309</epage><pages>301-309</pages><issn>0098-1532</issn><eissn>1096-911X</eissn><abstract>A combination of cyclophosphamide, adriamycin, methotrexate, and bleomycin (CAMB) was explored in patients with advanced, nonresectable epidermoid carcinoma from primary sites in the head and neck, recurrent or persistent after radiation or surgery. Objective regression (greater than 50%) of measurable tumor was present in 35% of the patients. The median duration of response was 2.5 months. Median survival of responders was slightly less than the nonresponders, but the difference was not significant. Drug‐related morbidity was substantial; leukopenia, mucositis, and weight loss were the most frequent major side effects. Three deaths were attributable to the regimen. The results seem comparable to those one might expect from methotrexate alone.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>85249</pmid><doi>10.1002/mpo.2950030312</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0098-1532 |
| ispartof | Medical and pediatric oncology, 1977, Vol.3 (3), p.301-309 |
| issn | 0098-1532 1096-911X |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_mpo_2950030312 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adult Bleomycin - administration & dosage Bleomycin - adverse effects Bleomycin - therapeutic use Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - mortality chemotherapy Cyclophosphamide - administration & dosage Cyclophosphamide - adverse effects Cyclophosphamide - therapeutic use Doxorubicin - administration & dosage Doxorubicin - adverse effects Doxorubicin - therapeutic use Drug Evaluation Drug Therapy, Combination epidermoid carcinoma Female head and neck cancer Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - mortality Humans Male Methotrexate - administration & dosage Methotrexate - adverse effects Methotrexate - therapeutic use |
| title | Chemotherapy of head and neck cancer: Combination treatment with cyclophosphamide, adriamycin, methotrexate, and bleomycin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T23%3A23%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chemotherapy%20of%20head%20and%20neck%20cancer:%20Combination%20treatment%20with%20cyclophosphamide,%20adriamycin,%20methotrexate,%20and%20bleomycin&rft.jtitle=Medical%20and%20pediatric%20oncology&rft.au=Wittes,%20Robert%20E.&rft.date=1977&rft.volume=3&rft.issue=3&rft.spage=301&rft.epage=309&rft.pages=301-309&rft.issn=0098-1532&rft.eissn=1096-911X&rft_id=info:doi/10.1002/mpo.2950030312&rft_dat=%3Cistex_cross%3Eark_67375_WNG_S6RDJLGN_Z%3C/istex_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/85249&rfr_iscdi=true |